Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

PD-L2 peptide-Montanide vaccine

A vaccine composed of a peptide derived from the immune checkpoint molecule programmed death ligand 2 (PD-L2) combined with the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Vaccination with PD-L2 peptide-montanide vaccine may mount an immune response against PD-L2 expressing cells. This may enhance T-cell proliferation, cytokine production, and T-cell mediated cytolysis. PD-L2 binding to its cognate receptor, programmed cell death protein 1 (PD-1; PDCD1; CD279), downregulates T-cell responses and enhances immune evasion. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens.
Synonym:PD-L2 peptide plus Montanide ISA-51 vaccine
PD-L2 peptide plus Montanide vaccine
programmed death ligand 2 peptide vaccine
Search NCI's Drug Dictionary